Variables Cases (N=26) Controls (N=78)
Gender Male 10 (38%) 29 (37.18%)
Female 16 (62%) 49 (62.82%)
Age Mean (±SD) 42.04 (11.86) 40.42 (9.96)
15-30 6 (23%) 10 (13%)
31-45 12 (46%) 45 (58%)
>46 8 (31%) 23 (30%)
Body Mass Index <18.5 20 (77%) 41 (53%)
≥18.5 6 (23%) 37 (47%)
Type of TB SPPTB 10 (38%) 55 (70%)
SNPTB  3(12%) 9 (12%)
EPTB 13 (50%) 14 (18%)
CD4+ cell count <50 15 (58%) 22 (29%)
51-100 4 (15%) 18 (23%)
100-200 6 (23%) 19 (24%))
>200 1 (4%) 19 (24%)
Hepatitis B co-infection Yes 7 (27%) 4 (5%)
No 19 (73%) 74 (95%)
WHO HIV/AIDS stage Stage 3 13 (50%) 64 (82%)
Stage 4 13 (50%) 14 (18%)
ARV before TB treatment Yes 19 (73%) 50 (64%)
No 7 (27%) 28 (36%)
ARV regimen EFV based 7 (37%) 18 (36%)
NVP based 11 (58%) 29 (58%)
Boosted PIs based 1 (5%) 3 (6%)
Anti-TB Regimen 2HRZES/1HRZE/5HRE 2 (8%) 9 (11%)
2HRZE/4HR 24 (92%) 69 (88%)
Cotrimoxazole Yes 18 (69%) 46 (59%)
No 8 (31%) 32 (41%)
Table 1: Demographic and clinical characteristics of the total 104 HIV/TB coinfected patients.
Goto home»